Inflammatory rhabdomyoblastic tumor: Clinicopathologic and genomic features, association with neurofibromatosis type 1, and progression to rhabdomyosarcoma
Pathology - Research and Practice · 2026-12 · 288 · 156700
DOI: 10.1016/j.prp.2026.156700 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pathology - Research and Practice, 2026-12. Verfasst von Tulio M Silva und 16 weiteren Autor:innen. Beteiligte Einrichtung: Anatomia Patològica, Vall d'Hebron Hospital Universitari, Vall d'Hebron Barcelona Hospital Campus, Passeig Vall d'Hebron 119-129, Barcelona, 08035, S…. Hauptthemen laut MEDLINE: Neurofibromatosis 1, Rhabdomyosarcoma. Die Arbeit nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fundació la Marató de TV3.
Abstract (Originalsprache)
Inflammatory rhabdomyoblastic tumor (IRMT) is a rare myogenic neoplasm with a morphologic spectrum and incompletely defined clinical behavior. It is characterized by a prominent inflammatory infiltrate, skeletal muscle differentiation, and recurrent near-haploidization, with occasional progression to rhabdomyosarcoma. Its relationship with neurofibromatosis type 1 (NF1) remains incompletely understood, despite recurrent NF1 alterations and reports of IRMT arising in patients with NF1. We analyzed five IRMTs: three conventional tumors, one tumor with increased mitotic activity without overt malignant features, and one malignant tumor. Two arose in patients with clinically overt NF1 and Targeted next-generation sequencing identified pathogenic NF1 alterations in four out of five tumors, supporting an association between IRMT and NF1. Whole-genome sequencing demonstrated near-haploid genomes in conventional IRMTs, whereas the malignant tumor showed whole-genome duplication, genome-wide loss of heterozygosity, and homozygous CDKN2A inactivation. When included with other genomically characterized and published conventional IRMTs and malignant progressions, integrated data supports a view in which near-haploidization represents the genomic background of conventional IRMT, with complete CDKN2A inactivation and whole-genome duplication as candidate contributors to malignant progression. Although this small retrospective series cannot establish temporal sequence or causality, our findings provide additional clinicopathologic and molecular support for an association between IRMT and NF1 and further characterize the genomic alterations associated with malignant progression. Complete CDKN2A loss and whole-genome duplication should be regarded as candidate progression-associated findings requiring validation in larger cohorts and longitudinal and functional studies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Anatomia Patològica, Vall d'Hebron Hospital Universitari, Vall d'Hebron Barcelona Hospital Campus, Passeig Vall d'Hebron 119-129, Barcelona, 08035, Spain; Spanish Sarcoma Pathology Network (Imperas Project), Spain.
- Anatomia Patològica, Vall d'Hebron Hospital Universitari, Vall d'Hebron Barcelona Hospital Campus, Passeig Vall d'Hebron 119-129, Barcelona, 08035, Spain; Spanish Sarcoma Pathology Network (Imperas Project), Spain; Grup…
- Translational Genomics and Bioinformatics Group, Germans Trias I Pujol Research Institute, Can Ruti Campus, Badalona, Barcelona, Spain.
- Spanish Sarcoma Pathology Network (Imperas Project), Spain; Pathology Department, Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain; Departament de Ciències Morfològiques, Universitat Autònoma de B…
- Spanish Sarcoma Pathology Network (Imperas Project), Spain; Pathology Department, Hospital Universitario de Fuenlabrada, Fuenlabrada, Madrid, Spain.
- Anatomia Patològica, Vall d'Hebron Hospital Universitari, Vall d'Hebron Barcelona Hospital Campus, Passeig Vall d'Hebron 119-129, Barcelona, 08035, Spain.
Förderung
- Fundació la Marató de TV3
Zitieren
APA
Silva, T. M., Sesé, M., Magallón-Lorenz, M., Tapia, G., Tardío, J. C., Hernandez-Losa, J., Gel, B., Ciriaco, N., Alegría, A., Granados, R., Ramos-Oliver, I., Cucurull, M., Blanco, I., Valverde, C., Serrano, C., Serra, E., & Romagosa, C. (2026). Inflammatory rhabdomyoblastic tumor: Clinicopathologic and genomic features, association with neurofibromatosis type 1, and progression to rhabdomyosarcoma. Pathology - Research and Practice, 288, 156700. https://doi.org/10.1016/j.prp.2026.156700
Vancouver
Silva TM, Sesé M, Magallón-Lorenz M, Tapia G, Tardío JC, Hernandez-Losa J, et al. Inflammatory rhabdomyoblastic tumor: Clinicopathologic and genomic features, association with neurofibromatosis type 1, and progression to rhabdomyosarcoma. Pathology - Research and Practice. 2026;288:156700. doi:10.1016/j.prp.2026.156700
BibTeX
@article{Silva2026,
author = {Silva, Tulio M and Sesé, Marta and Magallón-Lorenz, Miriam and Tapia, Gustavo and Tardío, Juan C and Hernandez-Losa, Javier and Gel, Bernat and Ciriaco, Nikaoly and Alegría, Alejandro and Granados, Rosario and Ramos-Oliver, Irma and Cucurull, Marc and Blanco, Ignacio and Valverde, Claudia and Serrano, César and Serra, Eduard and Romagosa, Cleofé},
title = {Inflammatory rhabdomyoblastic tumor: Clinicopathologic and genomic features, association with neurofibromatosis type 1, and progression to rhabdomyosarcoma},
journal = {Pathology - Research and Practice},
year = {2026},
volume = {288},
pages = {156700},
doi = {10.1016/j.prp.2026.156700}
}
EUVIMED